These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 32463436

  • 1. Longitudinal Microperimetric Changes of Macular Sensitivity in Stargardt Disease After 12 Months: ProgStar Report No. 13.
    Schönbach EM, Strauss RW, Muñoz B, Wolfson Y, Ibrahim MA, Birch DG, Zrenner E, Sunness JS, Ip MS, Sadda SR, West SK, Scholl HPN, ProgStar Study Group.
    JAMA Ophthalmol; 2020 Jul 01; 138(7):772-779. PubMed ID: 32463436
    [Abstract] [Full Text] [Related]

  • 2. Macular Sensitivity Measured With Microperimetry in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 7.
    Schönbach EM, Wolfson Y, Strauss RW, Ibrahim MA, Kong X, Muñoz B, Birch DG, Cideciyan AV, Hahn GA, Nittala M, Sunness JS, Sadda SR, West SK, Scholl HPN, ProgStar Study Group.
    JAMA Ophthalmol; 2017 Jul 01; 135(7):696-703. PubMed ID: 28542693
    [Abstract] [Full Text] [Related]

  • 3. The Natural History of the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Studies: Design and Baseline Characteristics: ProgStar Report No. 1.
    Strauss RW, Ho A, Muñoz B, Cideciyan AV, Sahel JA, Sunness JS, Birch DG, Bernstein PS, Michaelides M, Traboulsi EI, Zrenner E, Sadda S, Ervin AM, West S, Scholl HP, Progression of Stargardt Disease Study Group.
    Ophthalmology; 2016 Apr 01; 123(4):817-28. PubMed ID: 26786511
    [Abstract] [Full Text] [Related]

  • 4. Microperimetry Features of Geographic Atrophy Identified With En Face Optical Coherence Tomography.
    Pilotto E, Convento E, Guidolin F, Abalsamo CK, Longhin E, Parrozzani R, Midena E.
    JAMA Ophthalmol; 2016 Aug 01; 134(8):873-9. PubMed ID: 27253760
    [Abstract] [Full Text] [Related]

  • 5. Progression of Stargardt Disease as Determined by Fundus Autofluorescence in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 9).
    Strauss RW, Muñoz B, Ho A, Jha A, Michaelides M, Cideciyan AV, Audo I, Birch DG, Hariri AH, Nittala MG, Sadda S, West S, Scholl HPN, ProgStar Study Group.
    JAMA Ophthalmol; 2017 Nov 01; 135(11):1232-1241. PubMed ID: 29049437
    [Abstract] [Full Text] [Related]

  • 6. The Progression of Stargardt Disease Using Volumetric Hill of Vision Analyses Over 24 Months: ProgStar Report No.15.
    Schönbach EM, Janeschitz-Kriegl L, Strauss RW, Cattaneo MEGV, Fujinami K, Birch DG, Cideciyan AV, Sunness JS, Weleber RG, Ip MS, Sadda SR, Scholl HPN, ProgStar Study Group.
    Am J Ophthalmol; 2021 Oct 01; 230():123-133. PubMed ID: 33951446
    [Abstract] [Full Text] [Related]

  • 7. Faster Sensitivity Loss around Dense Scotomas than for Overall Macular Sensitivity in Stargardt Disease: ProgStar Report No. 14.
    Schönbach EM, Strauss RW, Ibrahim MA, Janes JL, Birch DG, Cideciyan AV, Sunness JS, Muñoz B, Ip MS, Sadda SR, Scholl HPN, ProgStar Study Group.
    Am J Ophthalmol; 2020 Aug 01; 216():219-225. PubMed ID: 32222369
    [Abstract] [Full Text] [Related]

  • 8. Incidence of Atrophic Lesions in Stargardt Disease in the Progression of Atrophy Secondary to Stargardt Disease (ProgStar) Study: Report No. 5.
    Strauss RW, Muñoz B, Ho A, Jha A, Michaelides M, Mohand-Said S, Cideciyan AV, Birch D, Hariri AH, Nittala MG, Sadda S, Scholl HPN, ProgStar Study Group.
    JAMA Ophthalmol; 2017 Jul 01; 135(7):687-695. PubMed ID: 28542697
    [Abstract] [Full Text] [Related]

  • 9. Multimodal analysis of the Preferred Retinal Location and the Transition Zone in patients with Stargardt Disease.
    Verdina T, Greenstein VC, Sodi A, Tsang SH, Burke TR, Passerini I, Allikmets R, Virgili G, Cavallini GM, Rizzo S.
    Graefes Arch Clin Exp Ophthalmol; 2017 Jul 01; 255(7):1307-1317. PubMed ID: 28365912
    [Abstract] [Full Text] [Related]

  • 10. Macular function and morphologic features in juvenile stargardt disease: longitudinal study.
    Testa F, Melillo P, Di Iorio V, Orrico A, Attanasio M, Rossi S, Simonelli F.
    Ophthalmology; 2014 Dec 01; 121(12):2399-405. PubMed ID: 25097154
    [Abstract] [Full Text] [Related]

  • 11. En Face Spectral-Domain Optical Coherence Tomography for the Monitoring of Lesion Area Progression in Stargardt Disease.
    Melillo P, Testa F, Rossi S, Di Iorio V, Orrico A, Auricchio A, Simonelli F.
    Invest Ophthalmol Vis Sci; 2016 Jul 01; 57(9):OCT247-52. PubMed ID: 27409479
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Scotopic Microperimetric Assessment of Rod Function in Stargardt Disease (SMART) Study: Design and Baseline Characteristics (Report No. 1).
    Strauss RW, Kong X, Bittencourt MG, Ho A, Jha A, Schönbach EM, Ahmed MI, Muñoz B, Ervin AM, Michaelides M, Birch DG, Sahel JA, Sunness JS, Zrenner E, Bagheri S, Ip M, Sadda S, West S, Scholl HPN, for the SMART Study Group.
    Ophthalmic Res; 2019 Jul 01; 61(1):36-43. PubMed ID: 29940588
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Morpho-functional correlation of fundus autofluorescence in Stargardt disease.
    Parodi MB, Iacono P, Triolo G, La Spina C, Zucchiatti I, Cicinelli MV, Borrelli E, Manitto MP, Martina E, Bandello F.
    Br J Ophthalmol; 2015 Oct 01; 99(10):1354-9. PubMed ID: 25837607
    [Abstract] [Full Text] [Related]

  • 16. Longitudinal changes in microperimetry and low luminance visual acuity in age-related macular degeneration.
    Wu Z, Ayton LN, Luu CD, Guymer RH.
    JAMA Ophthalmol; 2015 Apr 01; 133(4):442-8. PubMed ID: 25632841
    [Abstract] [Full Text] [Related]

  • 17. Asymmetric Inter-Eye Progression in Stargardt Disease.
    Lambertus S, Bax NM, Groenewoud JM, Cremers FP, van der Wilt GJ, Klevering BJ, Theelen T, Hoyng CB.
    Invest Ophthalmol Vis Sci; 2016 Dec 01; 57(15):6824-6830. PubMed ID: 28002570
    [Abstract] [Full Text] [Related]

  • 18. The Progression of Stargardt Disease as Determined by Spectral-Domain Optical Coherence Tomography over a 24-Month Period (ProgStar Report No. 18).
    Strauss RW, Lang L, Ho A, Jha A, Ip M, Bernstein PS, Birch DG, Cideciyan AV, Michaelides M, Audo I, Sunness JS, Traboulsi EI, Zrenner E, Sadda SR, Janeschitz-Kriegl L, West S, Kong X, Scholl HPN, ProgStar Study Group.
    Ophthalmic Res; 2024 Dec 01; 67(1):435-447. PubMed ID: 39004077
    [Abstract] [Full Text] [Related]

  • 19. Visual Acuity Change Over 24 Months and Its Association With Foveal Phenotype and Genotype in Individuals With Stargardt Disease: ProgStar Study Report No. 10.
    Kong X, Fujinami K, Strauss RW, Munoz B, West SK, Cideciyan AV, Michaelides M, Ahmed M, Ervin AM, Schönbach E, Cheetham JK, Scholl HPN, ProgStar Study Group.
    JAMA Ophthalmol; 2018 Aug 01; 136(8):920-928. PubMed ID: 29902293
    [Abstract] [Full Text] [Related]

  • 20. NEGATIVE VESSEL REMODELING IN STARGARDT DISEASE QUANTIFIED WITH VOLUME-RENDERED OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY.
    Reich M, Dreesbach M, Boehringer D, Schottenhamml J, Gehring E, Scholl HPN, Inglin N, Agostini H, Reinhard T, Lagrèze WA, Spaide RF, Lange C, Maloca PM.
    Retina; 2021 Sep 01; 41(9):1948-1957. PubMed ID: 33438899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.